Pages that link to "Q37357251"
Jump to navigation
Jump to search
The following pages link to A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer (Q37357251):
Displaying 50 items.
- Antiangiogenic mechanisms and factors in breast cancer treatment (Q26751226) (← links)
- MicroRNAs and triple negative breast cancer (Q26862716) (← links)
- Breast cancer chemoprevention: old and new approaches (Q27693259) (← links)
- Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis (Q33622614) (← links)
- Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor (Q33647681) (← links)
- Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. (Q33739802) (← links)
- Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy (Q33802940) (← links)
- Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study (Q34048813) (← links)
- Present and future evolution of advanced breast cancer therapy (Q34274925) (← links)
- Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies (Q34562257) (← links)
- Antiangiogenic therapy for breast cancer (Q34989039) (← links)
- The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. (Q35023922) (← links)
- Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles (Q35889673) (← links)
- The molecular landscape of premenopausal breast cancer (Q35937970) (← links)
- Bevacizumab and breast cancer: what does the future hold? (Q36298210) (← links)
- Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease (Q36357360) (← links)
- Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation. (Q36507879) (← links)
- The VEGF pathway in cancer and disease: responses, resistance, and the path forward. (Q36526512) (← links)
- αB-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells (Q36838575) (← links)
- Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway (Q36947703) (← links)
- Role of epidermal growth factor receptor in breast cancer (Q37320346) (← links)
- Biomarkers for Basal-like Breast Cancer (Q37328394) (← links)
- Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. (Q37355708) (← links)
- Renal toxicity of targeted therapies (Q37473177) (← links)
- Emerging targeted combinations in the management of breast cancer (Q37593371) (← links)
- More is less -- combining targeted therapies in metastatic colorectal cancer (Q37639898) (← links)
- ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy (Q37662351) (← links)
- TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion (Q37663864) (← links)
- Targeting multiple kinase pathways: a change in paradigm (Q37705694) (← links)
- New therapeutic approaches in breast cancer (Q37818705) (← links)
- Recent Advances in Anti-Angiogenic Therapy of Cancer (Q37852512) (← links)
- ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective (Q37970020) (← links)
- Novel targeted agents for the treatment of advanced breast cancer (Q38008723) (← links)
- Antiangiogenic therapy in the management of breast cancer (Q38035101) (← links)
- Emerging targeted therapies in triple-negative breast cancer (Q38046585) (← links)
- Safety and feasibility of targeted agent combinations in solid tumours (Q38077440) (← links)
- Molecularly targeted therapies for metastatic triple-negative breast cancer (Q38077472) (← links)
- Emerging EGFR antagonists for breast cancer. (Q38211951) (← links)
- Metronomics: towards personalized chemotherapy? (Q38218923) (← links)
- Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis (Q38681598) (← links)
- Targeting the Breast Cancer Kinome (Q38836110) (← links)
- Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer (Q39167876) (← links)
- Beyond Antiangiogenesis: Intratumorally Injected Bevacizumab Plays a Cisplatin-Sensitizing Role in Squamous Cell Carcinomas in Mice (Q39539497) (← links)
- Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose Study (Q42601834) (← links)
- Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside (Q47104354) (← links)
- Targeted Therapies Against Growth Factor Signaling in Breast Cancer (Q47559665) (← links)
- Photo-immobilized EGF chemical gradients differentially impact breast cancer cell invasion and drug response in defined 3D hydrogels (Q49918151) (← links)
- Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study. (Q55128548) (← links)
- The paradoxical functions of EGFR during breast cancer progression (Q57118645) (← links)
- Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis (Q57466733) (← links)